secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001140361-24-017331
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics promotes Kaitlin Kestenberg to COO and SVP, Compliance
---------------------------------------------------------------------

- Kestenberg promoted from SVP, Compliance & Project Operations to COO and SVP, Compliance, effective April 1, 2024.
- Base salary of $460,000; annual target bonus of 50% of base salary.
- Granted options for 300,328 shares and 192,320 RSUs, each vesting over four years.
- Severance includes 12 months salary (or 15 months plus 1.5x bonus upon change of control) plus COBRA.
- Kestenberg has been with ADMA since 2011; prior roles at Acorda Therapeutics and Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/0001140361-24-017331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/ef20025617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-017331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer